| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec0024795f45a646ef64b3664ab8a26d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ffb067b4d0ab903187696d90fc65b6b8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B59-001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B59-002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0402
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C275-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C275-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B59-00 |
| filingDate |
2017-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1a03a3b537bbe429b0e765baa2886d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bd2052addc785c23330aa0a9797c8f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21e0a6cc6511b59f506fe6c0ac86c967
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84870ddf30c768bd76555f936a0ff231
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7554d992c23dbffccf7543ec3ab8dbfe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1cd2ed8432da3226c6c2fce124a284a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfe36685488548ab05dec73741677d3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_533f7d60cbfb1b1d5176522f1457038e |
| publicationDate |
2017-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017246327-A1 |
| titleOfInvention |
18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| abstract |
The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113677375-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020157128-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11738101-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113573743-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11491247-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114685599-A |
| priorityDate |
2014-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |